Description: Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Home Page: www.cytokinetics.com
CYTK Technical Analysis
350 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 624 3000
Officers
| Name | Title |
|---|---|
| Mr. Robert I. Blum | CEO, Pres & Director |
| Mr. Ching W. Jaw | Sr. VP & CFO |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Exec. VP of R&D |
| Mr. Andrew M. Callos | Exec. VP & Chief Commercial Officer |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Jeff Lotz | VP of Sales & Operations |
| Mr. Robert C. Wong | VP & Chief Accounting Officer |
| Ms. Joanna Siegall | Associate Director of Corp. Communications & Investor Relations |
| Ms. Kari K. Loeser J.D. | VP & Chief Compliance Officer |
| Mr. Scott R. Jordan | Sr. VP of Global Marketing & Commercial Strategy |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 31.8985 |
| Price-to-Sales TTM: | 27.5151 |
| IPO Date: | 2004-04-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 253 |